In July 2026, an external advisory panel selected by the Department of Health and Human Services recommended that the FDA remove compounding restrictions on six out of seven reviewed peptides, including BPC-157

From the articleTrump Administration Advances Plan for Peptides Favored by RFK Jr.Also in Trump administration advances plan for peptide drugs favored by RFK Jr., US FDA takes step to change peptide compounding policy | Reuters